How to buy Bionomics stock

Bionomics is a biotechnology business based in the US. Bionomics shares (BNOX) are listed on the NASDAQ and all prices are listed in US Dollars.

Bionomics stock price (NASDAQ: BNOX)

Use our graph to track the performance of BNOX stocks over time.

Bionomics shares at a glance

• Key figures

Information last updated 2023-01-26.

Latest market close	$4.28
52-week range	$3.51 - $12.99
50-day moving average more info button	$5.88
200-day moving average more info button	$7.20
Wall St. target price	$12.33
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-2.16

Buy Bionomics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Bionomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bionomics price performance over time

Historical closes compared with the close of $4.275 from 2023-01-27

1 week (2023-01-23)	2.76%
1 month (2022-12-30)	-8.06%
3 months (2022-10-31)	-48.18%
6 months (2022-07-29)	-34.73%

1 year (2022-01-31)	-61.93%
2 years (2021-01-27)	N/A
3 years (2020-01-27)	N/A
5 years (2018-01-27)	N/A

Bionomics financials

Revenue TTM	$6.1 million
Gross profit TTM	$-9,943,677
Return on assets TTM	-18.4%
Return on equity TTM	-41.64%
Profit margin	0%
Book value	$7.56
Market capitalisation more info button	$29.8 million

TTM: trailing 12 months

Bionomics share dividends

We're not expecting Bionomics to pay a dividend over the next 12 months.

You may also wish to consider:

• Merck-and-Company (MRK.US) (2.66% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (2.69% forward annual dividend yield)
• UnitedHealth Group Incorporated (UNH.US) (1.34% forward annual dividend yield)

Bionomics share price volatility

Over the last 12 months, Bionomics's shares have ranged in value from as little as $3.51 up to $12.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionomics's is 2.3714. This would suggest that Bionomics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Bionomics's beta into context you can compare it against those of similar companies.

• Merck-and-Company (MRK.US): 0.3931
• Johnson-and-Johnson (JNJ.US): 0.5706
• UnitedHealth Group Incorporated (UNH.US): 0.7279

Bionomics overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. .

Frequently asked questions

What percentage of Bionomics is owned by institutions?
Currently 20.063% of Bionomics shares are held by institutions. When does the fiscal year end for Bionomics?
Bionomics's fiscal year ends in June. Where is Bionomics based?
Bionomics's address is: 200 Greenhill Road, Eastwood, SA, Australia, 5063 What is Bionomics's ISIN number?
Bionomics's international securities identification number is: US09063M2052